Skip to main content
PMC home page
Springer logoLink to Springer
. 2023 Jul 17;270(9):4583. doi: 10.1007/s00415-023-11864-2

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

Eugenio Mercuri 1,2,✉, Andrés Nascimento Osorio 3, Francesco Muntoni 4,5, Filippo Buccella 6, Isabelle Desguerre 7, Janbernd Kirschner 8, Már Tulinius 9, Maria Bernadete Dutra de Resende 10, Lauren P Morgenroth 11, Heather Gordish-Dressman 12, Shelley Johnson 13, Allan Kristensen 13, Christian Werner 14, Panayiota Trifillis 13, Erik K Henricson 15, Craig M McDonald 15; the STRIDE and CINRG DNHS investigators
PMCID: PMC10421802  PMID: 37460854

Correction to: Journal of Neurology 10.1007/s00415-023-11687-1

The original version of this article unfortunately contained a mistake. There are 2 data errors in the results section of the abstract.

In abstract, first sentence of the results section should read as

As of January 31, 2022, 307 patients were enrolled from 14 countries. Mean (standard deviation [SD]) ages at first symptoms and at genetic diagnosis were 2.9 (1.7) years and 5.4 (3.1) years, respectively. Mean (SD) duration of ataluren exposure was 1671 (566.8) days.

Articles from Journal of Neurology are provided here courtesy of Springer

RESOURCES